The group will review emerging data and shape Ochre鈥檚 development plans around patients鈥� unmet needs: ensuring its programs address critical gaps in liver disease, defining how they will complement existing treatments, and guiding the evidence generated to demonstrate meaningful, differentiated benefit.

Led by Eduardo Martins, the CTB will advise on translational and clinical strategy across MASH, alcohol-associated liver disease and patients with cirrhosis. It will work alongside Ochre鈥檚 Scientific Strategy Board, which will continue to guide the evolution of the company鈥檚 discovery platform and future programs.

The CTB comprises:

• Eduardo Martins, MD, DPhil: Former Chief Medical Officer at Sagimet Biosciences, with extensive clinical development experience, including leading the clinical development of cenicriviroc for NASH at AbbVie.
• Scott L. Friedman, MD: Director of the Center for Liver Research at Mount Sinai and a pioneer in understanding the causes of liver fibrosis.
• Chinweike Ukomadu, MD, PhD: Head of Takeda鈥檚 Gastrointestinal and Inflammation Therapeutic Area Unit and former head of gastroenterology and liver translational medicine at Novartis.
• Wajahat Mehal, MD, DPhil: Professor of Medicine and Director of the Fatty Liver Disease Program at Yale, with expertise in inflammation, fibrosis and preclinical and clinical drug development.
• Robert H. Scannevin, PhD: Chief Scientific Officer at GondolaBio and former Chief Scientific Officer at Verge Genomics, where he advanced multiple first-in-class programs into clinical development. He brings more than 25 years of experience spanning discovery, translational research and early clinical development.
• Martijn van de Bunt, MD, PhD: Former Chief Scientific Officer at Cytoki Pharma, with more than 15 years of cardiometabolic drug development experience spanning translational and clinical development leadership. Previously led global bioinformatics and data science teams across early research and clinical development at Novo Nordisk.

Quin Wills, Founder and CEO of 91制片厂, said: 鈥淥chre was founded on three pillars: better discovery, better validation, and better translation. As we begin moving our therapies out of the lab, our CTB will help us realise the final pillar of translating great science into patient impact.鈥�

About 91制片厂

91制片厂 is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. 91制片厂 is headquartered in Oxford, UK, and has research labs in New York and Taipei.

The post 91制片厂 announces Clinical Translation Board to guide development of new liver therapies appeared first on 91制片厂.

The two extensive datasets include:

• A large-scale functional聽genomics dataset from primary human hepatocytes, created by systematically knocking down all known hepatocyte genes in multiple donors and profiling downstream effects with RNA sequencing.
• A single-cell聽dataset built from perfused human donor livers, capturing gene expression across different cell types and donors.

The collaboration now transitions into a multi-year co-exclusive license agreement, granting both parties the ability to use Ochre-generated proprietary human liver data to accelerate the discovery and development of new treatments for liver diseases.

Ochre’s proprietary OBELiX software further integrates these datasets with proprietary disease atlases, combining gene perturbation data with clinical phenotypes. Together, these resources enable a causal mapping of gene function to proprietary disease signatures across pathways and cell types.

By revealing how different liver cell populations contribute to liver disease progression, the collaboration provides foundational data for training AI models and understanding promising therapeutic targets.

Quin Wills, founder and CEO of 91制片厂 said: “To develop therapies that truly impact the lives of liver patients, we cannot compromise on building large-scale human datasets. Datasets that move beyond population genetics, allowing us to causally explore the complexities of human disease biology. These foundational datasets developed with GSK feed our algorithms (AI) to do just that.”

Kaivan Khavandi, SVP, Head of Respiratory, Immunology & Inflammation at GSK said: “Our collaboration with Ochre has generated data that supports our deepened understanding of human biology and disease. This data feeds our AI models and helps power our work to discover and develop new medicines for liver diseases for patients who are waiting.”

About 91制片厂

91制片厂 is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. 91制片厂 is headquartered in Oxford, UK, and has research labs in New York and Taipei.

Media Contact:

ochre@coulsonpartners.com             +44 7752 329 851

The post 91制片厂 Completes Human Liver Functional Genomics and Single-cell Datasets in Partnership with GSK appeared first on 91制片厂.